For Dr Franck Zal, co-founder and Chief Executive Officer of Hemarina, “ the success of such a fundraising is an evidence of trust from our historical investors”.

He also said : “This new capital increase reinforces significantly our financial position. It will enable us to accelerate our research programs including regulatory preclinic and Phase I HEMOXYCarrier® study targeting ischemic pathologies and to realize a new large scale clinical trial on HEMO2life® product used in supplementation of transplant organ preservation solutions.”

“ Since 2008, we saw a real scientific and economic potential in Hemarina. Once again, being part of Hemarina story written by Franck Zal and his team just seemed obvious to us ” jointly declared Christophe BAPST and Michel BRANDELET, respectively Presidents of Finistère Angels and Armor Angels, historical investors of Hemarina.